Introduction {#Sec1}
============

Infantile cortical hyperostosis (ICH), also known as Caffey disease or Caffey--de Toni--Silverman disease, is an inflammatory collagenopathy, manifested by subperiosteal bone hyperplasia and soft tissue swelling, most commonly affecting the mandible, clavicles, and diaphyses of long bones.^[@CR1]^ Two different forms of the disease have been described: prenatal and infantile. The prenatal form is divided into severe and mild subtypes, based on time of onset: before and after 35 weeks of gestation, respectively. The infantile form has an onset within the first 6 months of life and in the majority of cases resolves spontaneously by the age of 2 years.

The pathophysiology of ICH is not completely understood. It is assumed that inflammation plays a role, as demonstrated by leukocytosis and elevated erythrocyte sedimentation rate. In addition, treatments with anti-inflammatory drugs such as glucocorticoids or nonsteroidal anti-inflammatory drugs have been proven to be helpful.^[@CR2]^

ICH is considered to be a genetic disease. In several reports, researchers investigated familial cases and hypothesized that the pattern of inheritance might be autosomal dominant with incomplete penetrance and variable expressivity.^[@CR3]^ In 2005, Gensure et al.^[@CR4]^ confirmed the autosomal-dominant trait of ICH by performing a genome-wide analysis of three unrelated families presenting the disease. The researchers found a novel missense mutation in the *COL1A1* gene on chromosome 17q21. This mutation is a 3040C\>T transition, resulting in the substitution of the amino acid Arginine by Cysteine at position 836 (R836C) within the helical domain of the a1 chain of type 1 collagen. This finding places ICH within the group of type 1 collagen-related conditions, such as osteogenesis imperfecta and Ehlers--Danlos syndrome.^[@CR5]^ Following this report, patients with ICH expressing the *COL1A1* mutation were reported worldwide,^[@CR6]--[@CR11]^ and even one lethal prenatal genetic case of ICH was described.^[@CR12]^

Interestingly, in several ICH patients, this previously known mutation in *COL1A1* was not identified nor were other novel mutations found for this gene.^[@CR4],[@CR11]^ Some cases of ICH were suggested to be sporadic rather than genetic and were thought to differ from the familial form, as can sometimes be attributed to exposure to prostaglandin E1 and prostaglandin E2.^[@CR13],[@CR14]^ It was also hypothesized that ICH might have an autosomal-recessive inheritance form^[@CR15]--[@CR17]^; nevertheless, no specific mutation has so far been described.

Here we present an infant with clinical features of ICH, in whom the known mutation in *COL1A1* was not detected. The parents of the patient were first-degree cousins, thus an autosomal-recessive inheritance was highly suspected and investigated by our team.

Methods {#Sec2}
=======

Patient and data analysis {#Sec3}
-------------------------

The patient record was obtained from the e-record registry of our hospital. The patient was examined by the authors. Informed consent was obtained, and all procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Exome sequencing analysis and Sanger sequencing {#Sec4}
-----------------------------------------------

Whole-exome sequencing (WES) was performed at the Dr. von Hauner Children's Hospital NGS facility. Genomic DNA was isolated from whole blood of the patient for generation of whole-exome libraries using the SureSelect XT Human All Exon V5+UTR or V6+UTR Kit (Agilent Technologies, USA). Barcoded libraries were sequenced on a NextSeq 500 platform (Illumina, USA) with an average coverage depth of 100×. Bioinformatic analysis and subsequent filtering identified rare sequence variants. The familial segregation of this nucleotide change in the *AHSG* coding sequence was validated by the Sanger sequencing methodology.

Enzyme-linked immunosorbent assay (ELISA) for fetuin A {#Sec5}
------------------------------------------------------

Blood samples from the patient, his parents, and 19 healthy controls were collected in serum-separator tubes and allowed to coagulate for 30 min prior to centrifugation. Tubes were spun at 4000 RPM for 4 min in a non-refrigerated centrifuge. Serum was then pipetted and stored at −20 °C. Once all samples were recruited, serum samples were thawed at room temperature for 20 min and assayed using the quantitative sandwich ELISA technique (R&D Systems, Minneapolis, MN, USA). Assays were performed according to the suppliers' instructions. The assay was repeated twice.

Results {#Sec6}
=======

Case report {#Sec7}
-----------

A 9-week-old infant male presented to the clinic with right arm swelling that developed gradually over several weeks. No fever or systemic rash was found. There was no history of recent trauma or child abuse. The patient was the first-born child of consanguineous parents (first-degree cousins). He was born at term via cesarean section due to fetal distress. No relevant family medical history was found.

At presentation the patient was afebrile. Physical examination revealed a firmly swollen right arm, hard in consistency, without local erythema, or warmth. Radial pulse was palpable. A weak right grasping reflex was elicited. Laboratory results were notable for leukocytosis of 20 × 10^3^/ml (normal range for age: 5--19 × 10^3^/ml), alkaline phosphatase of 401 IU/l (normal range for age: 145--320 IU/l), elevated erythrocyte sedimentation rate of 70 mm/h (normal range for age: 3--13 mm/h), and C-reactive protein level of 150 mg/L (normal range for age: 0--5 mg/l). Basic coagulation profile was within normal limits.

X-ray of the right arm was performed, revealing exuberant periosteal reaction along the entire shaft of the right humerus (Fig. [1a](#Fig1){ref-type="fig"}). Further evaluation included a radiographic skeletal survey, which revealed significant periosteal reaction of one scapula, one fibula, the mandible, and many ribs (Fig. [1b](#Fig1){ref-type="fig"}). Based on the clinical and radiological findings, a diagnosis of ICH was made. Despite the possible transient nature of ICH, treatment with indomethacin (5 mg/kg per day) was started, and the lesions diminished completely within several months, as was demonstrated by follow-up radiographic examinations (Fig. [1c](#Fig1){ref-type="fig"}). After 1 year of follow-up, the patient was completely well with no bone deformity and/or elevated inflammatory markers. He is still on low dose of indomethacin (1 mg/kg per day).Fig. 1Patient's radiographic examinations. **a** Periosteal reaction along the entire shaft of the right humerus. **b** Periosteal reaction along the left clavicle, ribs, and mandible. **c** Periosteal reaction along the fibula. **d** Complete periosteal resolution of the humerus

Genetic evaluation {#Sec8}
------------------

Being a primary genetic candidate, the c.3040C\>T (p.R1014C) mutation in exon 41 of *COL1A1*^[@CR4]^ was sequenced using genomic DNA obtained from peripheral blood samples of the patient and both parents. The mutation was neither found in the patient nor in his parents. Therefore, a WES of the patient's gDNA was performed. Sequencing yielded 59,598 variants in recessive analysis, which affect protein sequences. This list of variants was subsequently reduced to 638 rare variants, by filtering out variants present in ≥0.01 of our in-house exomes and variants present with a minor allele frequency (MAF) ≥0.01 in GnomAD database. Recessive analysis reduced the variants list of the patient to 20 candidate genes (Table [1](#Tab1){ref-type="table"}). The most likely variant among these candidates that could affect bone remodeling and/or calcification was a nonsense mutation in lysine 2 of *AHSG* gene encoded protein, fetuin-A (c.4A\>T; p.K2X). The mutation was confirmed and segregation was validated by Sanger sequencing (Fig. [2](#Fig2){ref-type="fig"}).Table 1Whole-exome sequencing analysis, filtered for homozygous variantsCHRPOSGeneDescriptionREF/ALTMutationFREQCLIN REL1192780677RGS2Regulator of G-protein signaling 2A/GMissense0.00015N1196801005CFHR1Complement factor H related 1T/CMissense0.00003N1196801023CFHR1Complement factor H related 1C/TMissense0.00003N2118578823DDX18Dead box-helicase 18A/GMissense0.00003N3179462989USP13Ubiquitin-specific peptidase 13A/GMissense0N**3186330934AHSGAlpha 2-HS glycoproteinA/TStop0Y**5156750984CYFIP2Cytoplasmic FMR1 interacting protein 2A/GMissense0N5158743108IL12BInterleukin 12BG/ASplice region0.021N5158743788IL12BInterleukin 12BG/TMissense0.021N5159776690C1QTNF2C1q and TNF related 2G/AMissense0.00029N5161277824GABRA1Gamma aminobutyric acid type A receptor alpha1 subunitA/GMissense0N9139235336GPSM1G protein signaling modulator 1C/TMissense0.0001N1020019640MALRD1MAM and LDL receptor class A domain containing 1C/TMissense0N1021806568SKIDA1SKI/DACH domain containing 1G/AMissense0N1023290952ARMC3Armadillo repeat containing 3C/GMissense0.00001N12675281NINJ2Ninjurin2G/AMissense0.00013N2034800191EPB41L1Erythrocyte membrane protein band 4.1 like 1C/TSplice region0.00001N2046277813NCOA3Nuclear receptor coactivator 3C/TMissense0.00003NX84561276POF1BPremature ovarian failure, 1BC/AMissense0NY21751449TXLNG2PTaxilin gamma pseudogene, Y-linkedT/GSplice region0N*CHR* chromosome, *POS* position, *REF/ALT* reference/alternative allele, *FREQ* frequency in the population, *CLIN REL* clinical relevanceThe row describing the *AHSG* gene and mutation is in boldFig. 2Validation to the *AHSG* mutation. Sanger sequencing chromatograms confirmed segregation of the identified *AHSG* sequence variants in the patient and his parents. The first ATG codon of the encoded fetuin-A protein and the resulted TAG termination codon are boxed in red. The mutated nucleotide is marked with a blue arrow

Fetuin-A protein expression {#Sec9}
---------------------------

In order to confirm that the stop codon in position 2 of the predicted fetuin-A protein indeed causes a null protein, we detected in two separate experiments the fetuin-A serum levels of the patient, both his parents, ten age-matched healthy infants, and nine healthy adults using ELISA kit specific to serum fetuin-A (R&D Systems, Minneapolis, MN, USA).

The mean fetuin-A serum level among the infants control group was 1803.5 ± 515.63 μg/ml, whereas in two independent experiments no fetuin-A protein was detected in the patient's serum, indicating the deleterious mutation (*p* \< 0.001).

The serum fetuin-A levels of the parents were 592 and 626 μg/ml in the mother and father respectively, values which are compatible with the mean serum level of the healthy adult control group (576.1 ± 221.3 μg/ml; Table [2](#Tab2){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). This suggests that one wild-type (WT) allele of the *AHSG* gene is enough to produce the necessary amount of fetuin-A protein for normal function.Table 2AHSG serum levels, measured by ELISASampleSexAge (years)Fetuin-A level (μg/ml)Adult control group1F404822F397613M308754F206935M338296M444097F504208M282279F36489Infant control group1M217962F1.516073F210024M0.520715F517226M411407M422348M524979F6150210F42464Patient's parentsMother (1)F21535Mother (2)F21649Father (1)M24603Father (2)M24649Patient−1M1Negative−2M1Negative*AHSG* ALPHA-2-HS-GLYCOPROTEIN, *ELISA* enzyme-linked immunosorbent assayFig. 3Fetuin-A protein levels in the sera. The fetuin-A serum levels of the patient, both his parents, ten age-matched healthy infants, and nine healthy adults were measured, using the enzyme-linked immunosorbent assay kit specific to serum fetuin-A (R&D Systems, Minneapolis, MN, USA). The results are presented in μg/ml

Discussion {#Sec10}
==========

Here we present a possible association between a novel homozygous mutation in the *AHSG* gene and an infant male with typical clinical manifestations of ICH. *AHSG* is a protein-coding gene located at chromosome 3q27. The protein encoded by this gene is fetuin-A/alpha2-Heremans-Schmid-glycoprotein. Clinical diseases that are associated with genetic variants of *AHSG* include leanness,^[@CR18]^ Alopecia-Intellectual Disability Syndrome,^[@CR19]^ Epstein--Barr virus hepatitis,^[@CR20]^ and SARS coronavirus infection.^[@CR21]^ Fetuin-A is also correlated to the metabolic syndrome,^[@CR22]^ and its role as a cancer biomarker is investigated.^[@CR23],[@CR24]^ Fetuin-A is thought to be a regulator of normal bone calcification and an inhibitor of pathological ectopic mineralization and calcification therefore was suggested to be important for physiologic osteogenesis and bone remodeling.^[@CR25]^

Fetuin-A is a negatively charged glycoprotein (molecular weight 52 kDa), produced mainly by hepatocytes, secreted by the liver into the circulation, and accumulated in mineralized bone.^[@CR26]^ It is assumed that fetuin-A is produced in osteocytes as well and, to a far lesser extent, in osteoblasts, modulated by the bone-derived hormone FGF-23.^[@CR27]^ The protein is processed from a single chain precursor into its mature circulating form, which is composed of two N-terminal cystatin protein domains and a third proline-rich C-terminal domain. The amino-terminal domain D1 enables high affinity to calcium phosphate, forming soluble protein--mineral complexes ("mineral chaperones"), thereby preventing pathological calcification at enriched mineral sites.^[@CR28]^ In addition, fetuin-A functions as an antagonist to the transforming growth factor beta (TGF-β) and bone morphogenetic protein (BMP) superfamily of cytokines and in this manner controls tissue remodeling and inflammation in osteoblastic cells. Fetuin-A structure shares homology with the extracellular domain of TGF-β receptor type II, allowing fetuin-A to bind directly to TGF-β1 and TGF-β2 and with greater affinity to TGF-β-related BMPs (BMP-2, BMP-4, and BMP-6) and limit cytokine activity.^[@CR29]^ In vitro studies showed that, in cultures of rat bone marrow cells, fetuin-A binds to TGF-β cytokines and suppresses dexamethasone osteogenesis.^[@CR29],[@CR30]^

Since the model of *AHSG* knockout mice (Ahsg−/−) became available, researchers examined in vivo the role of fetuin-A in bone metabolism. In several studies, *AHSG*-deficient mice displayed severe extra-osseous calcifications of the kidney, heart, and lung, emphasizing the role of fetuin-A as an inhibitor of ectopic mineralization.^[@CR31],[@CR32]^ In other studies, *AHSG*-deficient mice presented a variety of pathological manifestations in physiological sites of mineralization such as long bones and growth plates: Seto et al.^[@CR33]^ showed that *AHSG*-deficient mice display increased cortical thickness in the femur, with increased mineral content in the growth plate cartilage matrix, a site of vigorous physiological mineralization. Rittenberg et al.^[@CR34]^ implanted human native BMP into hindquarter muscles of mice and showed that the ratio of cortical to cancellous bone was more than two-fold higher in Ahsg−/− mice compared to WT and also presented higher incidence of immature bone islands ("satellite ossification"). Szweras et al.^[@CR35]^ showed that mice lacking ASHG protein display growth plate defects, increased bone formation including cortical thickening, and enhanced cytokine-dependent osteogenesis. All these findings in mice highly point to a possible role of *AHSG* deficiency in the pathophysiology of Caffey disease, which is characterized by subperiosteal bone hyperplasia.

Clinically, elevated serum levels of fetuin-A were found to be correlated with a mild form of osteogenesis imperfecta,^[@CR36]^ whereas depressed levels of fetuin-A were observed in increased bone turnover conditions, such as Paget's disease.^[@CR37]^

Interestingly, a novel homozygous stop codon mutation in *AHSG* gene was found in our presented case who had typical features of infantile Caffey disease. This resulted in no production of fetuin-A in the patient, as detected by ELISA test. Taking into consideration the importance of fetuin-A in bone metabolism, we highly suspect that this *AHSG* gene defect is the cause of the ICH phenotype in our patient. These findings also support the theory that ICH can be inherited in an autosomal-recessive manner. Our discovery raises the possibility of potential treatments for ICH. For instance, in patients with pseudoxanthoma elasticum, a hereditary disease of ectopic mineralization in soft connective tissues caused by a known mutation in *ABCC6* gene, circulatory fetuin-A was found to be reduced.^[@CR38]^ Jiang et al.^[@CR39]^ suggested that normalization of serum fetuin-A, either through gene therapy or by direct protein delivery to the circulation, can be used to treat the disease. In this manner, based on our study, fetuin-A should also be considered as a treatment for ICH.

Our study has several limitations; we report only an association between fetuin-A deficiency and ICH phenotype, but no in vivo experiment was conducted in order to prove causation. However, as described above, previous studies that investigated *AHSG* knockout mice showed bone hyperplasia and cortical thickening resembling ICH manifestations. The novel stop codon mutation that we described causes zero production of fetuin-A. In other words, it is equivalent to knocking out the *AHSG* gene. Thus we consider this mutation to be the cause of ICH in our patient. We, therefore, propose that additional Caffey disease patients with non-*COL1A1* defects will be assessed for fetuin-A deficiency. It can be argued that our patient might have a "Caffey-like" disease with manifestations imitating the classic infantile Caffey disease described in the literature. However, the classic presentation in our patient, including the laboratory and imaging findings, as well as the prompt resolution of the symptoms, are all consistent with ICH, therefore we highly recommend additional ICH patients with non-*COL1A1* defects to be assessed for fetuin-A deficiency.

In conclusion, ICH is an underdiagnosed collagenopathy of infancy; hence, clinicians in general and pediatricians in particular should be aware of its unique presentation and proper management. ICH has a strong genetic basis; while an autosomal-dominant mutation in the *COL1A1* gene was previously reported, we are the first to report an association between a novel autosomal-recessive mutation in the *AHSG* gene and ICH. This homozygous nonsense mutation in lysine 2 of the *AHSG* encoded protein (c.4A\>T; p.K2X) caused null production of fetuin-A, revealing the importance of this protein in the pathogenesis of ICH. Treatment approaches for increasing fetuin-A levels among ICH patients should be considered and further investigated.
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